Clinical Trial Update: Irinotecan-based Triplet (FOLFOXIRI) as Perioperative Treatment in Resectable Gastric and Gastroesophageal Junction Adenocarcinoma. [Phase 2]

View source ↗

Summary

An ongoing Phase 2 trial evaluates an irinotecan-based triplet (FOLFOXIRI) as perioperative therapy for resectable gastric and gastroesophageal junction adenoca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Resectable Gastric and Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Irinotecan (Irinotecan)
• Leucovorin (folinic acid)
• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: Lund University Hospital | Conditions: Resectable Gastric and Gastroesophageal Junction Adenocarcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING